- Ph I trial showed reduction in biomarker associated with anti-tumor activity in animal models
- There were no serious or dose-limiting adverse events in the Ph I trial
- Aravive... read more
Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced on 8/16/18 positive topline results from a Phase 3, randomized, double-blind,... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,